SGPGI Lucknow Hepatitis C Study Proves Shorter Treatment Works Just as Well

Medical researchers in our city have achieved a major breakthrough that could soon ease the financial and physical toll of chronic illness. An SGPGI Lucknow hepatitis C study published recently in The Lancet demonstrates that shortening treatment duration by four weeks achieves virtually the same cure rate as standard protocols. Conducted across multiple top-tier public hospitals, the trial changes how clinicians approach this stubborn liver infection.

For patients navigating public healthcare corridors in Uttar Pradesh, long pharmaceutical protocols often mean missed wages, logistical friction, and mounting medicine costs. This landmark clinical trial proves that an eight-week course of sofosbuvir-velpatasvir successfully cures hepatitis C in 98.8% of patients. That figure sits right alongside the 99.0% cure rate delivered by the traditional 12-week regimen.

A Collaborative Clinical Effort Across North India

Public health trials of this scale require deep institutional synergy. The collaborative research brought together Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) and King George’s Medical University (KGMU) right here in Lucknow, alongside Banaras Hindu University’s Institute of Medical Sciences (BHU-IMS) in Varanasi, New Delhi’s AIIMS, and GB Pant Hospital. Statistical heavy-lifting also came from Lucknow’s own CSIR-Central Drug Research Institute (CDRI).

The trial enrolled a substantial cohort of 880 patients across these five publicly funded tertiary-care centers over a period spanning more than a year. By tracking patients carefully through sustained virological response milestones, the medical teams established that dropping four weeks from the prescription schedule does not compromise efficacy.

• 880 total patients evaluated across five major public hospitals
• 98.8% sustained virological response achieved in the eight-week treatment group
• 99.0% cure rate recorded in the standard 12-week control group

Why It Matters for Patients and Public Health

Shorter treatment windows reduce pill burdens, lower hospital visitation frequencies, and shrink overall costs for state healthcare systems. When combined with other pressing local infrastructure updates, such as the Lucknow Municipal Corporation budget: ₹5,319-Crore Plan Approved for City Infrastructure, medical research advancements show how our institutions drive national policy. Public health delivery often faces strain, much like what is observed when the Gorakhpur flood situation turns grim as Saryu and Rapti swell across eastern Uttar Pradesh, making every efficiency gain in hospitals vital for community resilience.

Administrative pressures also ripple across educational and civic spaces in the region, echoing debates seen when the Uttar Pradesh Division Demand Returns to Center Stage Ahead of 2027 Elections or when student communities raise concerns, as noted in reports on the LU Students Protest Nearly Fourfold Hostel Fee Hike at Ranveer Singh Bisht Hostel. Even campus management faces routine hurdles, similar to findings regarding the Stray dog menace on PGI campus exposes enforcement gaps despite Supreme Court orders. Yet, pure scientific research from our local medical stalwarts continues to earn global recognition.

Cutting four weeks off therapy without losing effectiveness gives doctors a powerful tool to simplify hepatitis treatment compliance across India.

Looking Ahead

As policymakers digest the data from The Lancet publication, state health departments are expected to review guidelines for regional clinics. For residents of Lucknow and the broader UP diaspora tracking medical milestones back home, this study reinforces the city’s position as a heavyweight in specialized healthcare delivery.

Sources:

• Hindustan Times: Four weeks less, nearly same cure rate for hepatitis C, SGPGI-led study